aTYR PHARMA INC (ATYR) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, aTYR PHARMA reported revenue of $190,000, down 19.1% from $235,000 the year before. Net income was -$74.1M (a -39009.5% net margin), or -$0.80 per diluted share. Operating margin was -40856.3%. Operating activities generated -$62.0M of cash, leaving -$62.1M of free cash flow. At fiscal year end, aTYR PHARMA held $93.0M in total assets against $25.5M in total liabilities, including $10.7M of cash and equivalents.
Open the full interactive aTYR PHARMA financials → Quarterly statements, key ratios, valuation history and price charts.
aTYR PHARMA Key Stats
| Share Price | $0.20 |
|---|---|
| Market Cap | $19.7M |
| Revenue YoY Growth | -19.1% |
| 52-Week Range | $0.20 – $1.05 |
| Shares Outstanding | 98.1 million (basic, 2026 Q2) |
aTYR PHARMA Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $10.5M | $0 | $10.4M | $353,000 | $235,000 | $190,000 |
| Operating Income | -$15.9M | -$34.0M | -$46.4M | -$54.9M | -$67.9M | -$77.6M |
| Pre-Tax Income | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| Diluted EPS | -$1.77 | -$1.77 | -$1.60 | -$0.94 | -$0.86 | -$0.80 |
aTYR PHARMA Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $190,000 | $0 | $0 | $0 |
| Net Income | -$25.7M | -$14.0M | -$10.8M | -$10.3M |
| Diluted EPS | -$0.26 | -$0.15 | -$0.11 | -$0.11 |
aTYR PHARMA Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.0M | $2.3M | $10.0M | $22.5M | $11.1M | $10.7M |
| Current Assets | $35.5M | $113.6M | $80.9M | $103.0M | $82.0M | $80.2M |
| Total Assets | $38.7M | $115.5M | $95.8M | $120.7M | $96.8M | $93.0M |
| Current Liabilities | $5.9M | $6.0M | $13.9M | $16.4M | $15.0M | $15.1M |
| Total Liabilities | $7.1M | $6.2M | $24.3M | $30.0M | $26.8M | $25.5M |
| Shareholders' Equity | $31.6M | $109.3M | $71.5M | $90.7M | $70.0M | $67.5M |
aTYR PHARMA Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$15.3M | -$33.1M | -$41.9M | -$33.2M | -$69.1M | -$62.0M |
| Cash From Investing | $6.9M | -$91.6M | $47.2M | -$20.1M | $17.2M | -$5.1M |
| Cash From Financing | $16.1M | $110.0M | $5.5M | $66.2M | $39.9M | $66.0M |
| Free Cash Flow | -$15.5M | -$33.3M | -$43.5M | -$37.4M | -$69.2M | -$62.1M |
Figures from aTYR PHARMA's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full aTYR PHARMA financials page for every line item.
aTYR PHARMA Company Profile
| Ticker | ATYR |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001339970 |
Frequently Asked Questions
What was aTYR PHARMA's revenue in fiscal 2025?
aTYR PHARMA (ATYR) reported revenue of $190,000 for fiscal 2025.
What is aTYR PHARMA's annual revenue history?
aTYR PHARMA's annual revenue by fiscal year: 2020: $10.5M; 2021: $0; 2022: $10.4M; 2023: $353,000; 2024: $235,000; 2025: $190,000.
What was aTYR PHARMA's net income in fiscal 2025?
aTYR PHARMA reported net income of -$74.1M for fiscal 2025.
What was aTYR PHARMA's earnings per share (EPS) in fiscal 2025?
aTYR PHARMA's diluted EPS was -$0.80 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did aTYR PHARMA generate in fiscal 2025?
aTYR PHARMA generated -$62.1M of free cash flow in fiscal 2025.
What was aTYR PHARMA's revenue last quarter?
In its most recent reported quarter (2026 Q2), aTYR PHARMA reported revenue of $0.
How many shares of aTYR PHARMA are outstanding?
aTYR PHARMA reported a weighted average of 98.1 million basic shares outstanding in 2026 Q2.
What is aTYR PHARMA's market cap?
Based on its latest closing price, aTYR PHARMA (ATYR) has a market capitalization of about $19.7M.
When does aTYR PHARMA's fiscal year end?
aTYR PHARMA's fiscal year end, as registered with the SEC, is December 31.
Where is aTYR PHARMA headquartered?
aTYR PHARMA lists its business address in San Diego, California in its SEC filings.
aTYR PHARMA Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →